Icon plc Stock
Pros and Cons of Icon plc in the next few years
Pros
Cons
Performance of Icon plc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Icon plc | 0.740% | 1.094% | 5.044% | 56.166% | 14.391% | - | - |
Alkermes plc | -1.790% | 0.901% | 0.000% | -21.127% | -10.400% | 23.757% | -0.885% |
Ironwood Pharmaceuticals | 1.680% | -20.667% | -19.048% | -35.676% | -41.667% | -37.696% | - |
Sage Therapeutics Inc. | 1.350% | -6.678% | -25.356% | -78.130% | -46.200% | -82.413% | - |
Comments
News
ICON releases its ICON Cares 2023 Report
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2023 Report. This outlines how the company is delivering on its
ICON Announces Pricing of USD 2 Billion Notes
ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting
ICON Reports First Quarter 2024 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2024.
CEO, Dr